MiR-101-3p Improves Neuronal Morphology and Attenuates Neuronal Apoptosis in Ischemic Stroke in Young Mice by Downregulating HDAC9

Overview

Journal Transl Neurosci

Specialty Neurology

Date 2023 May 30

PMID 37250142

Authors

Mengru Zhang

Jianjun Wang

Jinfang Li

Fanxin Kong

Songjun Lin

Affiliations

Soon will be listed here.

Abstract

Objective: MiRNAs play a key role in ischemic stroke (IS). Although miR-101-3p can participate in multiple disease processes, its role and mechanism in IS are not clear. The aim of the present study was to observe the effect of miR-101-3p activation on IS in young mice and the role of HDAC9 in this effect.

Methods: The young mice were first subjected to transient middle cerebral artery occlusion (tMCAO) or sham surgery, and the cerebral infarct area was assessed with 2,3,5-triphenyltetrazolium chloride staining. Meanwhile, the expressions of miR-101-3p and HDAC9 were tested using RT-qPCR or western blot. Besides, neuron morphology and apoptosis were confirmed using Nissl staining and TUNEL staining.

Results: We first verified that miR-101-3p was downregulated and HDAC9 was upregulated in the brain tissue of tMCAO young mice. Moreover, we proved that overexpression of miR-101-3p could improve cerebral infarction, neuronal morphology, and neuronal apoptosis in tMCAO young mice by lowering the expression of HDAC9.

Conclusions: Activation of miR-101-3p can protect against IS in young mice, and its mechanism is relevant to the inhibition of HDAC9. Therefore, miR-101-3p and HDAC9 might be the latent targets for IS therapy.

Citing Articles

Epigenetic regulation of iron metabolism and ferroptosis in Parkinson's disease: Identifying novel epigenetic targets.

Gao X, Ding J, Xie J, Xu H Acta Pharmacol Sin. 2025; .

PMID: 40069488 DOI: 10.1038/s41401-025-01499-6.

Hypoxia-Induced miR-101 Impairs Endothelial Barrier Integrity Through Altering VE-Cadherin and Claudin-5.

Shukla A, Bhardwaj U, Apoorva , Seth P, Singh S Mol Neurobiol. 2023; 61(3):1807-1817.

PMID: 37776496 DOI: 10.1007/s12035-023-03662-8.

The Role of microRNAs in Epigenetic Regulation of Signaling Pathways in Neurological Pathologies.

Tregub P, Ibrahimli I, Averchuk A, Salmina A, Litvitskiy P, Manasova Z Int J Mol Sci. 2023; 24(16).

PMID: 37629078 PMC: 10454825. DOI: 10.3390/ijms241612899.

References

Kalayinia S, Arjmand F, Maleki M, Malakootian M, Singh C . MicroRNAs: roles in cardiovascular development and disease. Cardiovasc Pathol. 2020; 50:107296. DOI: 10.1016/j.carpath.2020.107296. View

Chauhan G, Debette S . Genetic Risk Factors for Ischemic and Hemorrhagic Stroke. Curr Cardiol Rep. 2016; 18(12):124. PMC: 5086478. DOI: 10.1007/s11886-016-0804-z. View

Chen J, Cui C, Yang X, Xu J, Venkat P, Zacharek A . MiR-126 Affects Brain-Heart Interaction after Cerebral Ischemic Stroke. Transl Stroke Res. 2017; 8(4):374-385. PMC: 5604242. DOI: 10.1007/s12975-017-0520-z. View

Sarikaya H, Steinlin M . Cerebellar stroke in adults and children. Handb Clin Neurol. 2018; 155:301-312. DOI: 10.1016/B978-0-444-64189-2.00020-2. View

Xin Y, Tang L, Chen J, Chen D, Wen W, Han F . Inhibition of miR‑101‑3p protects against sepsis‑induced myocardial injury by inhibiting MAPK and NF‑κB pathway activation via the upregulation of DUSP1. Int J Mol Med. 2021; 47(3). PMC: 7849984. DOI: 10.3892/ijmm.2021.4853. View

Meng X, Sun Y, Liu S, Mu Y . miR-101-3p sensitizes lung adenocarcinoma cells to irradiation via targeting BIRC5. Oncol Lett. 2021; 21(4):282. PMC: 7905603. DOI: 10.3892/ol.2021.12543. View

Cepparulo P, Cuomo O, Vinciguerra A, Torelli M, Annunziato L, Pignataro G . Hemorrhagic Stroke Induces a Time-Dependent Upregulation of miR-150-5p and miR-181b-5p in the Bloodstream. Front Neurol. 2021; 12:736474. PMC: 8580415. DOI: 10.3389/fneur.2021.736474. View

Mu J, Cheng X, Zhong S, Chen X, Zhao C . Neuroprotective effects of miR-532-5p against ischemic stroke. Metab Brain Dis. 2020; 35(5):753-763. DOI: 10.1007/s11011-020-00544-z. View

Wagenaar N, Martinez-Biarge M, van der Aa N, van Haastert I, Groenendaal F, Benders M . Neurodevelopment After Perinatal Arterial Ischemic Stroke. Pediatrics. 2018; 142(3). DOI: 10.1542/peds.2017-4164. View

10.

Kalogeris T, Baines C, Krenz M, Korthuis R . Ischemia/Reperfusion. Compr Physiol. 2017; 7(1):113-170. PMC: 5648017. DOI: 10.1002/cphy.c160006. View

11.

Buckowski A, Rose E . Pediatric stroke: diagnosis and management in the emergency department. Pediatr Emerg Med Pract. 2019; 16(11):1-20. View

12.

Ferriero D, Fullerton H, Bernard T, Billinghurst L, Daniels S, DeBaun M . Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke. 2019; 50(3):e51-e96. DOI: 10.1161/STR.0000000000000183. View

13.

Hou F, Li D, Yu H, Kong Q . The mechanism and potential targets of class II HDACs in angiogenesis. J Cell Biochem. 2017; 119(4):2999-3006. DOI: 10.1002/jcb.26476. View

14.

Zheng T, Shi Y, Zhang J, Peng J, Zhang X, Chen K . MiR-130a exerts neuroprotective effects against ischemic stroke through PTEN/PI3K/AKT pathway. Biomed Pharmacother. 2019; 117:109117. DOI: 10.1016/j.biopha.2019.109117. View

15.

Bu L, Xie Y, Lin D, Chen Y, Jing X, Liang Y . LncRNA-T199678 Mitigates α-Synuclein-Induced Dopaminergic Neuron Injury via miR-101-3p. Front Aging Neurosci. 2020; 12:599246. PMC: 7732511. DOI: 10.3389/fnagi.2020.599246. View

16.

Zhang L, Lu Q, Chang C . Epigenetics in Health and Disease. Adv Exp Med Biol. 2020; 1253:3-55. DOI: 10.1007/978-981-15-3449-2_1. View

17.

Zhang Y, Sun Z, Jia J, Du T, Zhang N, Tang Y . Overview of Histone Modification. Adv Exp Med Biol. 2020; 1283:1-16. DOI: 10.1007/978-981-15-8104-5_1. View

18.

Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

19.

Longa E, Weinstein P, Carlson S, Cummins R . Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989; 20(1):84-91. DOI: 10.1161/01.str.20.1.84. View

20.

Guzik A, Bushnell C . Stroke Epidemiology and Risk Factor Management. Continuum (Minneap Minn). 2017; 23(1, Cerebrovascular Disease):15-39. DOI: 10.1212/CON.0000000000000416. View